Research programme: nitric oxide scavengers - Curacyte

Drug Profile

Research programme: nitric oxide scavengers - Curacyte

Latest Information Update: 01 May 2007

Price : $50

At a glance

  • Originator Curacyte AG
  • Developer Curacyte AG; Curacyte Inc
  • Class
  • Mechanism of Action Nitric oxide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Uveitis

Most Recent Events

  • 01 May 2007 Discontinued - Preclinical for Uveitis in USA (unspecified route)
  • 10 Jun 2002 VitaResc Biotech has been acquired by, and merged into, Curacyte AG
  • 31 Oct 2001 Preclinical development for Uveitis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top